SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Atrium Therapeutics, Inc. (RNA) News

Track canonical SquawkNews coverage tagged to RNA, Atrium Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol RNA Asset equity Sector Markets 90 days 9 Last 8.43 Updated Sep 21, 2026, 08:30 PM UTC Open live news feed
L RNA - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) RNA - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NEWS | Sep 21, 2026, 08:30 PM UTC L New biotech advances RNA therapeutics for rare cardiomyopathies New biotech advancing RNA therapeutics for rare genetic cardiomyopathies. Lead PRKAG2 program is in phase I/II, with proof-of-concept data expected next year, alongside strategic collaborations and a broader pipeline. EQUITY | Sep 08, 2026, 01:39 PM UTC L New biotech advances RNA therapies for rare genetic cardiomyopathies Unresolved biotech is advancing RNA therapeutics for rare genetic cardiomyopathies, focusing on PRKAG2 and PLN syndromes. Lead program is in Phase I/II, with proof-of-concept data expected next year and strategic partner EQUITY | Sep 08, 2026, 01:04 PM UTC L RNA - Atrium Therapeutics to Participate in Upcoming Investor Conferences RNA - Atrium Therapeutics to Participate in Upcoming Investor Conferences EQUITY | Sep 02, 2026, 12:01 PM UTC L Atrium Therapeutics announces inducement grants under Nasdaq Rule 5635(c)(4) Atrium Therapeutics (RNA) announces inducement grants under Nasdaq Listing Rule 5635(c)(4), per the company’s release. REGULATION | Aug 20, 2026, 10:25 PM UTC L Atrium Therapeutics reports Second Quarter 2026 financial results Atrium Therapeutics (RNA) reports its Second Quarter 2026 financial results, per TradeXchange Newsdesk, with no figures or additional detail included in the feed. EARNINGS | Aug 13, 2026, 08:45 PM UTC L MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued C MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP Protection in GEOPOLITICS | Jul 20, 2026, 08:06 PM UTC L Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome () -- Atrium Therapeutics (RNA) said Tuesday the US Food and Drug Administration cleared its investigational new drug application for its lead product candidate ATR 1072, allowing the company to advance a phase 1/2 clini REGULATION | Jul 14, 2026, 11:18 AM UTC L Atrium Therapeutics announces FDA clearance of ATR 1072 IND application Atrium Therapeutics... REGULATION | Jul 14, 2026, 10:36 AM UTC